Trump’s Second Term: Unraveling Global Pharma Supply Chains

President Donald Trump's return to office in 2025 has ushered in a series of policy shifts impacting global pharmaceutical supply chains. Notably, Executive Order 14169 initiated a 90-day pause on U.S. foreign development assistance, leading to immediate disruptions in programs, which supports HIV treatment across Africa.
Simultaneously, the administration's move to withdraw from the World Health Organization has further strained international health collaborations. In South Africa, these decisions resulted in the loss of over 8,000 health worker positions and the closure of specialized HIV clinics, undermining years of progress in combating the epidemic.
On the trade front, proposed tariffs on imported pharmaceuticals aim to bolster domestic manufacturing but risk increasing drug costs and disrupting supply chains. Africa, reliant on imports for essential medicines, faces potential shortages and price hikes, exacerbating existing healthcare challenges.
These geopolitical maneuvers underscore the fragility of global health systems and the interconnectedness of pharmaceutical logistics. As nations grapple with these changes, the need for resilient, diversified supply chains becomes paramount.
We invite you to share your perspectives on these developments. Connect with us on LinkedIn and explore our insights at https://www.ipharmalogistics.com/contact-us